PNA-neamine conjugates and methods for producing and using the same
View Patent ↗The present invention relates to methods and compositions pertaining to conjugates composed of a peptide nucleic acid (PNA) moiety and a neamine derivative moiety. Methods for using such conjugates for modulating the activity of a target nucleic acid molecule and for preventing or treating a disease associated with an aberrant nucleic acid molecule are also provided.
1. A composition for modulating the activity of a nucleic acid molecule comprising a peptide nucleic acid moiety conjugated to a neamine moiety, wherein said composition is of Formula I
wherein, at least one of R 1 , R 2 , R 3 , or R 4 is a peptide nucleic acid which hybridizes with one or more nucleic acid molecules and the remaining substituents, R 1 , R 2 , R 3 , R 4 , and R 5 , are each independently a hydrogen, a neamine, a lipophilic chain, a reactive or catalytic group, or a binding element.
2. A method for producing a composition of claim 1 comprising the steps of:
a) protecting amino functions of the neamine moiety with an acid-labile protecting group;
b) protecting hydroxyl functions of the neamine moiety with a protecting group which produces an acid-labile ether;
c) conjugating R 1 , R 2 , R 3 , R 4 , or R 5 substituents to the neamine moiety, wherein at least one of R 1 , R 2 , R 3 , or R 4 is a peptide nucleic acid which hybridizes with one or more nucleic acid molecules; and
d) deprotecting the amino and hydroxyl functions and recovering the peptide nucleic acid-neamine conjugate.
3. A method for modulating the activity of a nucleic acid molecule comprising contacting one or more nucleic acid molecules with a composition of claim 1 which hybridizes with at least one nucleic acid molecule of the one or more nucleic acid molecules so that the function of the at least one nucleic acid molecule is modulated.
4. A method for preventing or treating a disease associated with an aberrant nucleic acid molecule comprising administering to a patient with a disease associated with an aberrant nucleic acid molecule located within a T lymphocyte an effective amount of a composition of claim 1 which hybridizes with the aberrant nucleic acid molecule located within the T lymphocyte so that the function of the aberrant nucleic acid molecule is modulated and the disease associated with said aberrant nucleic acid molecule is prevented or treated.